BTIG Research Lowers Obalon Therptcs (OBLN) Price Target to $15.00
Obalon Therptcs (NASDAQ:OBLN) had its target price reduced by equities researchers at BTIG Research from $20.00 to $15.00 in a report released on Monday. The brokerage presently has a “buy” rating on the stock. BTIG Research’s price objective points to a potential upside of 67.41% from the stock’s previous close.
A number of other research analysts have also issued reports on OBLN. Northland Securities restated a “sell” rating and set a $6.00 price target on shares of Obalon Therptcs in a research note on Wednesday, August 2nd. UBS AG restated a “buy” rating and set a $20.00 price target (down previously from $22.00) on shares of Obalon Therptcs in a research note on Thursday, August 3rd. Finally, Zacks Investment Research lowered shares of Obalon Therptcs from a “hold” rating to a “sell” rating in a research note on Tuesday, August 8th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $14.00.
Obalon Therptcs (NASDAQ OBLN) opened at $8.96 on Monday. The company has a quick ratio of 13.14, a current ratio of 13.29 and a debt-to-equity ratio of 0.20.
Obalon Therptcs (NASDAQ:OBLN) last posted its quarterly earnings data on Friday, November 3rd. The company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.12). The firm had revenue of $2.79 million for the quarter, compared to the consensus estimate of $2.95 million. Obalon Therptcs had a negative return on equity of 56.19% and a negative net margin of 459.54%. research analysts predict that Obalon Therptcs will post -1.81 earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: This story was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this story can be viewed at https://www.watchlistnews.com/btig-research-lowers-obalon-therptcs-obln-price-target-to-15-00/1682349.html.
A number of institutional investors have recently modified their holdings of OBLN. Kornitzer Capital Management Inc. KS boosted its holdings in shares of Obalon Therptcs by 0.5% in the 2nd quarter. Kornitzer Capital Management Inc. KS now owns 422,410 shares of the company’s stock valued at $4,186,000 after acquiring an additional 2,075 shares during the last quarter. California State Teachers Retirement System boosted its holdings in shares of Obalon Therptcs by 53.5% in the 2nd quarter. California State Teachers Retirement System now owns 15,200 shares of the company’s stock valued at $151,000 after acquiring an additional 5,300 shares during the last quarter. Bank of New York Mellon Corp boosted its holdings in shares of Obalon Therptcs by 33.9% in the 2nd quarter. Bank of New York Mellon Corp now owns 21,135 shares of the company’s stock valued at $210,000 after acquiring an additional 5,353 shares during the last quarter. UBS Group AG boosted its holdings in shares of Obalon Therptcs by 90.8% in the 1st quarter. UBS Group AG now owns 11,856 shares of the company’s stock valued at $127,000 after acquiring an additional 5,641 shares during the last quarter. Finally, Royal Bank of Canada boosted its holdings in shares of Obalon Therptcs by 6.7% in the 2nd quarter. Royal Bank of Canada now owns 91,499 shares of the company’s stock valued at $907,000 after acquiring an additional 5,732 shares during the last quarter. Institutional investors and hedge funds own 44.73% of the company’s stock.
Obalon Therptcs Company Profile
Obalon Therapeutics, Inc is a United States-based commercial-stage medical device company focused on developing and commercializing medical devices to treat obese and overweight people by facilitating weight loss. The Company’s product, Obalon balloon system, is a swallowable, gas-filled intragastric balloon designed to provide weight loss in obese patients.
Receive News & Ratings for Obalon Therptcs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Obalon Therptcs and related companies with Analyst Ratings Network's FREE daily email newsletter.